Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 15/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018335 | 0.81 | TAAR1 (0.56) | TAAR1 | |
| SCHEMBL12947588 | 0.80 | TSHR (0.43) | APPTSHRKIF11 | |
| SCHEMBL28326928 | 0.80 | TSHR (0.43) | APPTAAR1TSHR | |
| SCHEMBL5149729 | 0.79 | TAAR1 (0.48) | TAAR1TSHR | |
| SCHEMBL12452414 | 0.78 | PLK1 (0.50) | APPTSHR | |
| SCHEMBL26267723 | 0.77 | MAPT (0.67) | TAAR1MAPT | |
| SCHEMBL26268908 | 0.77 | TAAR1 (0.62) | TAAR1MAPT | |
| SCHEMBL26268878 | 0.77 | MAPT (0.49) | TAAR1MAPT | |
| SCHEMBL291602 | 0.76 | ALDH1A1 (0.52) | APPTSHRMAPTKIF11 | |
| SCHEMBL5689956 | 0.76 | CA2 (0.52) | APPTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447046-B2 | Histone demethylase inhibitors | Celegene Quanticel Research, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160107995-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107995-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6A, KDM1A | APP 4761/4885TAAR1 4273/4885TSHR 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.